Wockhardt

Indian pharma develops more effective drug to combat antibiotic-resistance

Wockhardt's nafithromycin is India's first FDA-approved antimicrobial that is seen as an alternative to existing antibiotics like azithromycin, which is facing increasing resistance in humans

Wockhardt Q2 results: Net loss narrows to Rs 16 cr, revenue at Rs 809 cr

Drug firm Wockhardt on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024. The company has reported a net loss of Rs 73 crore in July-September quarter of last fiscal. Revenue from operations stood at Rs 809 crore for the second quarter as compared with Rs 753 crore in the year-ago period, the Mumbai-based drug maker said in a regulatory filing. Shares of the company were trading 0.63 per cent up at Rs 1,189 apiece on BSE.

This pharma stock has zoomed over 380% in Samvat 2080; trades at 8-yr high

Wockhardt shares surged 5% to Rs 1,212.55, its highest level since February 2016 and has zoomed 157% thus far in the calendar year 2024.

Wockhardt gains 4% on filing for DCGI's approval for its insulin injection

Wockhardt is also developing additional insulin analogs and GLP-1 agonists to provide advanced diabetes care solutions

Wockhardt locks in 5% upper circuit as it nears approval for pneumonia drug

A positive response from CDSCO will give a push to the company efforts to gain the Drugs Controller General of India's (DCGI) final approval for Miqnaf

Wockhardt gets favourable recommendation from CDSCO for antibiotic for CABP

Drug firm Wockhardt on Friday said the national drug regulator has accorded a favourable recommendation for its novel antibiotic developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has provided a favourable recommendation for Miqnaf (nafithromycin), the drug firm said in a statement. The SEC recommendation is based on CDSCO's comprehensive review of the product dossier consisting of non-clinical, US/EU Phase 1, Global Phase 2 and India Phase 3 clinical studies conducted over the last 15 years, it added. A positive opinion from the SEC of CDSCO would pave the way for gaining DCGI's final approval for Miqnaf, the company stated. Miqnaf is the once-a-day 3-days-only treatment for CABP patients, including those caused by multi-drug resistant (MDR) bugs. CABP is the most common infection, leading to hospitalisation and death. Globally, 2.4 million annual dea

US FDA grants fast track status to Wockhardt's novel antibiotic WCK 6777

WCK 6777 is a once-a-day, β-lactam enhancer used for outpatient parenteral antimicrobial therapy

Congress vs Sebi chief Buch: Trading strategies in M&M, Pidilite, Wockhardt

After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.

Wockhardt denies Carol Info rent payment allegations, link with Sebi orders

Drug firm Wockhardt has denied allegations regarding payment of rent by Carol Info Services and its connection with certain orders passed by SEBI in relation to the company. "In this regard, we categorically deny these allegations and state that these allegations are completely baseless and misleading," Wockhardt said in a regulatory filing late Friday. It said the company has acted and continues to act in compliance with all applicable laws. On Friday, the Congress' media and publicity department head, Pawan Khera said that between 2018 and 2024, Madhabi Buch - as a whole-time member and later chairperson of Securities and Exchange Board of India (SEBI) - had been receiving rental income amounting to Rs 2.16 crore from Carol Info Services, a company affiliated to Wockhardt. Mumbai-based Wockhardt was being investigated by SEBI for various cases, including that of insider trading during 2023, he said at a press conference at the AICC headquarters in Delhi.

Wockhardt falls 5% after Congress alleges Sebi head of conflict of interest

This came after the Congress party accused Securities and Exchange Board of India (Sebi) chairperson Madhabi Puri Buch of a conflict of interest involving the pharmaceutical firm Wockhardt

Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end

Global launch in FY26 after multinational clinical trial ends

Wockhardt, Brigade Ent, Medplus Health among six stocks to watch on May 29

Stocks to watch on May 29: Wockhardt reported its Q4 earnings, disclosing a net loss of Rs 177 crore compared to a loss of Rs 237 crore YoY

Wockhardt Q4 results: Net loss at Rs 177 cr, revenue rises to Rs 700 cr

Drug firm Wockhardt on Tuesday reported a consolidated net loss of Rs 177 crore for the fourth quarter ended March 31, 2024. The company had reported a net loss of Rs 237 crore in the January-March quarter of 2022-23. Revenue from operations stood at Rs 700 crore for the period under review as compared with Rs 678 crore in the same period of FY23, the Mumbai-based drugmaker said in a regulatory filing. For the year ended March 31, 2024, the company reported a net loss of Rs 472 crore against a net loss of Rs 621 crore in 2022-23 fiscal. Revenue from operations increased to Rs 2,798 crore in FY24 compared with Rs 2,651 crore in FY23. The company said its board approved the re-appointment of Habil Khorakiwala as Executive Chairman for a further term of five years with effect from March 1, 2025, to February 28, 2030. Shares of the company on Tuesday ended 0.49 per cent down at Rs 557.95 apiece on the BSE.

Wockhardt Hospitals launches early recovery program for liver transplant

The hospital group also claims that the ERP program improves the survival rate of the patients by approximately 2-3 per cent while enhancing patient outcomes through advanced techniques

Wockhardt Q3 results: Loss narrows to Rs 86 cr, revenue up marginally

Pharmaceuticals firm Wockhardt Ltd on Wednesday reported narrowing of consolidated net loss to Rs 86 crore for the third quarter ended December 31, 2023. The company had incurred a loss of Rs 102 crore in the third quarter last fiscal, Wockhardt Ltd said in a regulatory filing. Revenue from operations during the quarter under review stood at Rs 701 crore as compared to Rs 699 crore in the year-ago period, the company said. Total expenses were lower at Rs 796 crore as against Rs 803 crore in the same period last fiscal.

Stock of this small-cap pharma company has zoomed over 50% in last 3 weeks

Wockhardt hit a fresh 52-week high of Rs 334.50, surging 19% on the BSE in Thursday's intra-day trade on the back of heavy volumes

Wockhardt shareholders reject proposal to raise Rs 1,600 cr from promotor

Shareholders of Wockhardt have rejected a proposal to raise Rs 1,600 crore from a promoter entity, according to a regulatory filing. The board of Mumbai-based drug firm had sought shareholder approval for a related party transaction with Khorakiwala Holdings and Investments Pvt Ltd (KHIPL) to raise up to Rs 1,600 crore for a period of five years. KHIPL, a promoter entity, is an RBI registered NBFC. About 50.12 per cent votes came in against the proposal while 49.87 per cent of the votes polled favoured the resolution, Wockhardt said in a regulatory filing. In a note, proxy advisory firm IiAS said it had sought approval for the proposal but it was defeated. "Wockhardt's resolution for a related party transaction with Khorakiwala Holdings and Investments Pvt Ltd (KHIPL) for an amount up to Rs 1,600 crore for a period of five years, was defeated," it noted. IiAS said the proposed related party transaction with KHIPL was intended for borrowing of funds for an amount up to Rs 1,600 cr

Wockhardt shareholders reject resolution on related party transaction

Shareholders of pharma firm Wockhardt Ltd have rejected a resolution on a related party transaction that seeks to allow the company to raise up to Rs 1,600 crore from its promoter group firm Khorakiwala Holdings and Investments Pvt Ltd. At the company's annual general meeting held on August 14, the company had put ten resolutions, including the adoption of audited financial statements and the re-appointment of Murtaza Khorakiwala as Managing Director, for approval by the shareholders, all of which were approved except the related party transaction. All the resolutions mentioned in the notice of the 24th annual general meeting stand passed with the requisite majority except Resolution No 7 (approval of material related party transactions), which was not approved by the members, company secretary Virendra Bhatt said in the consolidated scrutiniser's report. In a regulatory filing, Wockhardt said out of the total valid votes cast, 50.13 per cent was against the ordinary resolution for

Wockhardt loss widens to Rs 136 cr in Q1 due to higher expenses

Pharmaceutical firm Wockhardt Ltd on Monday said its consolidated loss after tax widened to Rs 136 crore in the June quarter due to higher expenses. The company had posted a consolidated loss after tax of Rs 75 crore in the year-ago period, Wockhardt Ltd said in a regulatory filing. Consolidated revenue from operations stood at Rs 644 crore in the first quarter of the current fiscal as compared to Rs 595 crore a year ago, it added. Total expenses were higher at Rs 762 crore as against Rs 748 crore in the corresponding quarter a year ago, the company said.

Wockhardt charting a recovery riding on a promising new antibiotic

While global trials are on, doctors have started using one of company's antibiotics against superbugs to save lives